Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Oct 21, 2021 2:59pm
151 Views
Post# 34034053

RE:RE:RE:Dr. Mace Rothenberg, MD

RE:RE:RE:Dr. Mace Rothenberg, MDAlso the fact that they are hiring scientists, preclinical and clinical project managers can be added to the hint list. I guess Jim if his statement was genuine is disappointed cause the speculations of reaching over 700mg/m2 by this and thar date turn out to be SPECULATIONS.
palinc2000 wrote:

We have zero scientific data on Efficacy but we now have 4 fantastic hints 
1- The smiling KOL s during the Kol Event
2- Some kind of a retainer paid to a retired doctor with a great track record
3- Chinese sniffing around
4/ Paul is extremely excited on Phase 1
Did I miss anything on Efficacy?

I wish

 

SPCEO1 wrote: Glad to see you back!  I hope your health is not causing you any problems.

I think the hiring of him at this time is likely the biggest hint we have yet that good thigs are happening on the TH-1902 front. THTX already knows enough from the phase 1a trial to not bring him on if it was going to be a dud. While we may still not see any signs of efficacy in phase 1a, THTX likely knows the chances of seeing that in phase 1b are pretty good as they would not bring him on if they already knew the cancer program was going nowhere.

While the analysts have not yet figured out that something positive is likely happening with TH-1902, the addition of Dr. Rothenberg and the Chinese sniffing around THTX looking for a partnership deal are indications the industry has started to figure it out.
 

 

jfm1330 wrote: Oncology is going so bad that they just hired an expert advisor...



https://www.theratech.com/about/scientific-consultants-and-advisors

 




<< Previous
Bullboard Posts
Next >>